BACKGROUND: Cognitive impairment is a common nonmotor manifestation of Parkinson's disease, with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains to severe dementia. The International Parkinson and Movement Disorder Society commissioned the assessment of the clinimetric properties of cognitive rating scales measuring global cognitive performance in PD to make recommendations regarding their use. METHODS: A systematic literature search was conducted to identify the scales used to assess global cognitive performance in PD, and the identified scales were reviewed and rated as "recommended," "recommended with caveats," "suggested," or "listed" by the panel using previously established criteria. RESULTS: A total of 12 cognitive scales were included in this review. Three scales, the Montreal Cognitive Assessment, the Mattis Dementia Rating Scale Second Edition, and the Parkinson's Disease-Cognitive Rating Scale, were classified as "recommended." Two scales were classified as "recommended with caveats": the Mini-Mental Parkinson, because of limited coverage of executive abilities, and the Scales for Outcomes in Parkinson's Disease-Cognition, which has limited data on sensitivity to change. Six other scales were classified as "suggested" and 1 scale as "listed." CONCLUSIONS: Because of the existence of "recommended" scales for assessment of global cognitive performance in PD, this task force suggests that the development of a new scale for this purpose is not needed at this time. However, global cognitive scales are not a substitute for comprehensive neuropsychological testing. © 2017 International Parkinson and Movement Disorder Society.

Applied Neuroscience Research Group Central European Institute of Technology CEITEC Masaryk University Brno Czech Republic

Department of Neurology Safarik University Kosice Slovakia

Department of Neurology University Hospital of L Pasteur Kosice Slovakia

Department of Psychiatry Leiden University Medical Centre Leiden and Centre of Mental Health Care Delfland Delft Netherlands

Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania and Parkinson's Disease and Mental Health Research Education and Clinical Centers Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA

Department of Psychology University of Amsterdam Amsterdam The Netherlands

Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease Toronto Western Hospital Toronto Ontario Canada

National Centre of Epidemiology and CIBERNED Carlos 3 Institute of Health Madrid Spain

Rush University Medical Center Department of Neurological Sciences Section of Parkinson Disease and Movement Disorders Chicago Illinois USA

Sobell Department of Motor Neuroscience and Movement Disorders and the National Hospital for Neurology and Neurosurgery London UK

Komentář v

Mov Disord. 2018 Mar;33(3):499-500. doi: 10.1002/mds.27339. PubMed

Komentář v

Mov Disord. 2018 Mar;33(3):499. doi: 10.1002/mds.27329. PubMed

Zobrazit více v PubMed

Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.

Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain 2015;138:1454-1476.

Stebbins GT. Cognitive impairment screening scales. In: Sampaio C, Goetz CG, Schrag A. eds. Rating Scales in Parkinson's Disease. 2012;195-214.

Hely MA, Reid WGJ, Adena MA, Halliday GA, Morris JGL. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.

Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007;254:38-45.

Posada IJ, Benito-Leon J, Louis ED, et al. Mortality from Parkinson's disease: a population-based prospective study. Mov Disord 2011;26:2522-2529.

Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.

Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.

Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.

Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.

Jurica PJ, Leitten CL, Mattis S. Psychological Assessment Resources, 2001. Dementia Rating Scale-2 (DRS-2). Arch Clin Neuropsychol 2004;19:145-147.

Pagonabarraga J, Kulisevsky J, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008;23:998-1005.

Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A. Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease. Behav Neurol 1995;8:15-22.

Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-1228.

Katsarou Z, Bostantjopoulou S, Zikouli A, et al. Performance of Greek demented and nondemented subjects on the Greek version of the Mattis Dementia Rating Scale. A validation study. Int J Neurosci 2010;120:724-730.

Vitaliano PP, Breen AR, Russo J, Albert M, Vitiello MV, Prinz PN. The clinical utility of the Dementia Rating Scale for assessing Alzheimer patients. J Chron Dis 1984;37:743-753.

Matteau E, Dupré N, Langlois M, et al. Mattis Dementia Rating Scale 2: screening for MCI and dementia. Am J Alzheimers Dis Other Demen 2011;26:389-398.

Smith GE, Ivnik RJ, Malec JF, et al. Psychometric properties of the Mattis Dementia Rating Scale. Assessment 1994;1:123-131.

Marson DC, Dymek MP, Duke LW, Harrell LE. Subscale validity of the Mattis Rating Scale Dementia. Arch Clin Neuropsychol 1997;12:269-275.

Schmidt KS, Lieto JM, Kiryankova E, Salvucci A. Construct and concurrent validity of the Dementia Rating Scale-2 Alternate Form. J Clin Exp Neuropsychol 2006;28:646-654.

Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.

Dujardin K, Devos D, Duhem S, et al. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. J Neurol 2006;253:1154-1159.

Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-1230.

Matteau E, Dupre N, Langlois M, Provencher P, Simard M. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol 2012;25:100e6.

Bezdicek O, Michalec J, Nikolai T, et al. Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson's disease and normative data. Dement Geriatr Cogn Disord 2015;39:303-311.

Villeneuve S, Rodrigues-Brazete J, Joncas S, Postuma RB, Latreille V, Gagnon JF. Validity of the Mattis Dementia Rating Scale to detectmild cognitive impairment in Parkinson's disease and REM sleep behavior disorder. Dement Geriatr Cogn Disord 2011;31(3):210-217.

Ozdilek B, Kenangil G. Validation of the Turkish version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease. Clin Neuropsychol 2014;28:333-343.

Nie K, Zhang Y, Wang L, et al. A pilot study of psychometric properties of the Beijing version of Montreal Cognitive Assessment in patients with idiopathic Parkinson's disease in China. J Clin Neurosci 2012;19:1497-1500.

Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal Cognitive Assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord 2008;23:1043-1046.

Federico A, Maier A, Vianello G, et al. Screening for mild cognitive impairment in Parkinson's disease: comparison of the Italian versions of three neuropsychological tests. Parkinson Dis 2015;2015:681976.

Nazem S, Siderowf AD, Duda JE, et al. Montreal Cognitive Assessment performance in patients with Parkinson's disease with “normal” global cognition according to Mini-Mental State Examination Score. J Am Geriatr Soc 2009;57:304-308.

Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the Mini-Mental State Exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord 2008;23:297-299.

Gagnon JF, Postuma RB, Joncas S, Desjardins C, Latreille V. The Montreal Cognitive Assessment: a screening tool for mild cognitive impairment in REM sleep behavior disorder. Mov Disord 2010;25(7):936-940

Caspell-Garcia C, Simuni T, Tosun-Turgut D, et al. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS One 2017 [Epub ahead of print].

Chen L, Yub C, Zhangc N, Liud J, Liub W. Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study. Clin Neurol Neurosurg 2016;151:65-69.

Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA Well-suited screen for cognitive impairment in Parkinson's disease. Neurology 2010;75:1717-1725.

Lucza T, Karadi K, Kallai J, et al. Screening mild and major neurocognitive disorders in Parkinson's disease. Behav Neurol 2015;2015:983505.

Bezdicek O, Majerova V, Novak M, Nikolai T, Ruzicka E, Roth J. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Appl Neuropsychol Adult 2015;20:33-40.

Fengler S, Kessler J, Timmermann L, et al. Screening for cognitive impairment in Parkinson's disease: improving the diagnostic utility of the MoCA through subtest weighting. PLoS One 2016;11(7):e0158318.

Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738-1745.

Biundo R, Weis L, Bostanjopoulou S, et al. MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm 2016;123:431-438.

Fernández-Bobadilla R, Martinez-Horta S, Marin-Lahoz J, Horta-Barba A, Pagonabarraga J, Kulishevsky J. Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). Parkinsonism Relat Disord. 2017;43;73-77.

Santangelo G, Lagravinese G, Battini V, et al. The Parkinson's Disease-Cognitive Rating Scale (PD-CRS): normative values from 268 healthy Italian individuals. Neurol Sci 2017;38(5):845-853.

Serrano-Duenas M, Serrano M, Villena D, Granda D. Validation of the Parkinson's Disease-Cognitive Rating Scale Applying the Movement Disorder Society Task Force Criteria for Dementia Associated with Parkinson's Disease. Mov Disord Clin Pract 2016 [Epub ahead of print].

Martínez-Martín P, Prieto-Jurczynska C, Frades-Payo B. [Psychometric attributes of the Parkinson's Disease-Cognitive Rating Scale. An independent validation study]. Rev Neurol 2009;49:393-398.

Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord. 2013;28:1376-1383.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.

Serrano-Dueñas M, Calero B, Serrano S, Serrano M, Coronel P. Metric properties of the Mini-Mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease. Mov Disord 2010;25:2555-2562.

Isella V, Mapelli C, Morielli N, et al. Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinson's disease. Neurol Sci 2013;34:1751-1758.

Caslake R, Summers F, McConachie D, et al. The mini-mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease. Curr Aging Sci 2013;6:273-279.

Parrao-Díaz T, Chaná-Cuevas P, Juri-Claverías C, Kunstmann C, Tapia-Núñez J. [Evaluation of cognitive impairment in a population of patients with Parkinson's disease by means of the mini mental Parkinson test]. Rev Neurol 2005;40:339-344.

Larner AJ. Effect Size (Cohen's d) of cognitive screening instruments examined in pragmatic diagnostic accuracy studies. Dement Geriatr Cognit Disord Extra 2014;4:236-241.

Chou KL, Amick MM, Brandt J, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010;25:2501-2507.

Isella V, Mapelli C, Morielli N, et al. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog. Parkinsonism Related Disord 2013;19:1160-1163.

Serrano-Duenas M, Calero B, Serrano S, Serrano M, Coronel P. Metric properties of the mini-mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease. Mov Disord 2010;25:2555-2562.

Carod-Artal FJ, Martinez-Martin P, Kummer W, Ribeiro Lda S. Psychometric attributes of the SCOPA-COG Brazilian version. Mov Disord 2008;23:81-87.

Martinez-Martin P, Rodriguez-Blazquez C, Paz S, et al. Parkinson symptoms and health related quality of life as predictors of costs: a longitudinal observational study with linear mixed model analysis. PLoS One 2015;10:e0145310.

Reuter I, Mehnert S, Sammer G, Oechsner M, Engelhardt M. Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson's disease. J Aging Res 2012;2012:235765.

Isella V, Mapelli C, Morielli N, et al. Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog). Funct Neurol 2013;28:121-125.

Rektorova I, Balaz M. Neuropsychiatric aspects of the on/off phenomenon. In: Aarsland D, Cummings J, Weintraub D, Chaudhuri K, eds. Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Disorders: Diagnosis and Management. Cambridge, UK: Cambridge University Press; 2013.

Caillava-Santos F, Margis R, Rieder CDR. Wearing-off in Parkinson's disease: neuropsychological differences between on and off periods. Neuropsychiatric Disease and Treatment 2015;11:1175-1180.

Starkstein SE, Robinson RG. Dementia of depression in Parkinson-disease and stroke. J Nervous Mental Dis 1991;179:593-601.

Pluck GC, Brown RG. Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatr 2002;73:636-642.

Leentjens AFG, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. Mov Disord 2008;23:2004-2014.

Goetz CG, Stebbins GT, Wang L, LaPelle N, Luo S, Tilley BC. The International Parkinson and Movement Disorder Society translation program for the MDS-UPDRS and UDysRS. Mov Disord 2014;29:S185.

Dubois B, Burn D, Goetz CG, et al. Diagnostic procedures for Parkinson's disease: Recommendations from the Movement Disorder Society Task Force. Mov Disord 2007;22:2314-2324.

Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrook's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psych 2006;21:1078-1085.

Yoshida H, Terada S, Honda H, et al. Validation of Addenbrook's cognitive examination for detecting early dementia in Japanese population. Psychiatry Res 2011;185:211-214

Reyes MA, Lloret SP, Gerscovich ER, Martin ME, Leiguarda R, Merello M. Addenbrooke's Cognitive Examination validation in Parkinson's disease. Eur J Neurol 2009;16:142-147.

McColgan P, Evans JR, Breen DP, Mason SL, Barker RA, Williams-Gray CH. Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. Mov Disord 2012;27:1172-1179.

Rittman T, Ghosh BC, McColgan P, et al. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatr 2013;84:544-551.

Rektorova I, Mekyska J, Janousova E, et al. Speech prosody impairment predicts cognitive decline in Parkinson's disease. Parkinsonism Relat Disord 2016;29:90-95.

Available at: https://www.medpagetoday.com/neurology/dementia/52040.

Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's Cogntive Examination III in frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 2013;36:242-250.

Clinical Outcome Assessments for Spasticity: Review, Critique, and Recommendations